Filtered By:
Specialty: Pharmaceuticals
Source: The Catalyst
This page shows you your search results in order of date.
Order by Relevance | Date
Total 150 results found since Jan 2013.
Key considerations as Congress works towards PAHPA reauthorization
This week, PhRMAsubmitted comments to the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) regarding the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization draft. In our comments, we expressed our strong opposition to policy proposals that would inhibit the biopharmaceutical industry partnering with the government to address pressing public health needs. With many PAHPA programs set to expire on September 30th and only a few legislative days left before the start of August work period, it is critical that lawmakers of both parties work together to ensure timely reauthorization of core pr...
Source: The Catalyst - July 12, 2023 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Research and Development Drug Cost Coronavirus Antimicrobial Resistance Source Type: news
A conversation with Dr. Mike Ybarra on the current state of COVID-19
On May 11th of this year, the COVID-19 national public health emergency (PHE) officially ended, marking an incredible milestone in the fight against COVID-19. While the end of the PHE signals a new chapter in the fight against COVID-19, the biopharmaceutical industry ’s work continues to ensure our health care system is well-prepared for any curve balls this virus might throw as well as staying ahead of the next pandemic.
Source: The Catalyst - June 27, 2023 Category: Pharmaceuticals Authors: Matthew Norawong Tags: Vaccines Coronavirus Antimicrobial Resistance Source Type: news
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
At the direction of the U.S. Trade Representative, the U.S. International Trade Commission (USTIC) is investigating the impact of a proposed waiver of intellectual property (IP) protections for COVID-19diagnostics and therapeutics under the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Public submissions to the USITC from experts across patient groups, academia, public health, labor and the private sector make clear that, much like the original TRIPS waiver for COVID-19 vaccines, the proposed expansion of the waiver to diagnostics and therapeutics is harmful and unnecessary.
Source: The Catalyst - April 13, 2023 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Vaccines Coronavirus TRIPS Waiver Source Type: news
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
At the request of the U.S. Trade Representative, the U.S. International Trade Commission (USITC) is conducting aninvestigation and will issue an accompanying report concerning theTRIPS Agreement and a variety of issues related to COVID-19 diagnostics and therapeutics. According to USTR, the USITC report will inform future discussions within the United States and at the World Trade Organization (WTO) concerningpotential TRIPS waiver expansion.
Source: The Catalyst - March 30, 2023 Category: Pharmaceuticals Authors: Kevin Haninger Tags: Intellectual Property Vaccines Coronavirus TRIPS Waiver Source Type: news
Celebrating the success of the COVID-19 vaccines, and looking to the future
It ’s been over three years since I saw my first COVID-19 patient in the emergency department. The image of that x-ray is burned into my memory: clusters of white spots spread out across both sides of the patient’s lung. A dramatic, and not all that common, clinical finding. The patient in front of me already had a fever and was breathing quickly, in need of extra oxygen support. I didn't know then the significance that patient would have on me, but three years later I think about them often, and how they marked the start of a three plus year journey that changed the world.
Source: The Catalyst - March 27, 2023 Category: Pharmaceuticals Authors: Michael Ybarra Tags: Research and Development Vaccines Coronavirus Government Price Setting Source Type: news
PhRMA submits comments to OSTP on enhancing clinical trial diversity
The White House ’s Office of Science and Technology Policy (OSTP) recently solicited stakeholder feedback on the clinical research infrastructure for emergency clinical trials, for which PhRMA submitted comments. PhRMA shares OSTP’s recognition of the importance of having a clinical trial infrastructure that su pports sites that are ready to respond to emergency situations like COVID-19. We also agree that one goal of such an infrastructure should be to support the expansion of clinical research into underserved communities by increasing diversity among both trial participants and clinical trial investigat ors.
Source: The Catalyst - March 21, 2023 Category: Pharmaceuticals Authors: Maria Apostolaros Tags: Research and Development Clinical Trials Coronavirus Source Type: news
What we ’ve learned from three years of fighting COVID-19
Three years ago, amidst an unprecedented public health crisis, biopharmaceutical industrymade a commitment to fight COVID-19. Leveraging decades of research and investments in emerging technologies and scientific expertise, we dedicated ourselves to finding medical solutions to prevent, diagnose and treat those impacted by the coronavirus.
Source: The Catalyst - March 20, 2023 Category: Pharmaceuticals Tags: Research and Development PhRMA Member Company Vaccines Coronavirus Source Type: news
U.S. must address IP and market access barriers abroad to protect American innovation
PhRMA recentlysubmitted comments to the Office of the U.S. Trade Representative (USTR) ’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine American innovation, biopharmaceutical leadership and more than 4.4 millionAmerican jobs.
Source: The Catalyst - January 31, 2023 Category: Pharmaceuticals Authors: Ernest Kawka Tags: Intellectual Property Coronavirus TRIPS Waiver Source Type: news
Word of the Month: What is TRIPS?
What is TRIPS?
Source: The Catalyst - November 29, 2022 Category: Pharmaceuticals Authors: Ernest Kawka and Douglas Petersen Tags: Vaccines Coronavirus TRIPS Waiver Word of the Month Source Type: news
TRIPS waiver expansion risks public health
The Biden administration and other World Trade Organization members are considering expanding the harmful and unnecessary waiver of intellectual property (IP) protections under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) beyond COVID-19 vaccines. These governments should approach this decision with a clear understanding of one of the most significant consequences of that action: compromised public health, especially in lower-income countries.
Source: The Catalyst - November 14, 2022 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Coronavirus TRIPS Waiver Source Type: news
Expanding the WTO intellectual property waiver will hurt American jobs
The June decision by WTO members to waive commitments to protect intellectual property (IP) for COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was a political and ineffective measure thatdoes not address the true barriers to vaccine equity. Now, some are pushing to extend this harmful waiver to COVID-19 treatments, even though production exceeds demand for treatments, including for the most effective antivirals and monoclonal antibodies. Allowing foreign governments and competitors to disregard IP protections will result in a loss of American jobs and hamper much-needed American innovation.
Source: The Catalyst - November 9, 2022 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Coronavirus TRIPS Waiver Source Type: news
Word of the Month: What is Long COVID?
What is Long COVID?
Source: The Catalyst - October 19, 2022 Category: Pharmaceuticals Authors: Mike Ybarra Tags: Vaccines Coronavirus Source Type: news
Word of the Month: Long COVID
What is Long COVID?
Source: The Catalyst - October 19, 2022 Category: Pharmaceuticals Authors: Mike Ybarra Tags: Vaccines Coronavirus Word of the Month Source Type: news
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Our industry is at the forefront of fighting the annual influenza virus. I recently had the chance to connect with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus about how the industry is working to fight the annual flu and what lessons learned during COVID-19 are allowing us to better respond to influenza.
Source: The Catalyst - October 13, 2022 Category: Pharmaceuticals Authors: Mike Ybarra Tags: PhRMA Member Company Vaccines Infectious Diseases Coronavirus Source Type: news
Partnerships are driving global COVID-19 treatment access
Through the constant efforts of U.S. innovators and their global partners,COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment landscape and the trajectory of the virus’ impact. This is in no small part due to the more than 140 collaborations for COVID-19 treatments that have been signed since the start of the pandemic, as reported to PhRMA by global data provider Airfinity.
Source: The Catalyst - September 22, 2022 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Vaccines Trade Coronavirus TRIPS Waiver Source Type: news
